Publications by authors named "F C Fandinho"

Article Synopsis
  • - The study focused on analyzing the genetic diversity of Mycobacterium tuberculosis (Mtb) isolates from drug-resistant tuberculosis patients in Brazil, finding a high prevalence of multidrug-resistant cases at 54.8% and pre-extensively drug-resistant cases at 9.2%.
  • - Researchers utilized whole-genome sequencing (WGS) to scrutinize 298 Mtb isolates, identifying the most common sub-lineage as 4.3 and uncovering 20 new mutations linked to drug resistance, with significant ongoing transmission among patients noted through genomic clustering.
  • - The in-house WGS pipeline outperformed online tools in predicting drug resistance, revealing key associations between certain genotypes and severe disease outcomes, which enhances the understanding of
View Article and Find Full Text PDF

Human tuberculosis (TB) is caused by members of the Mycobacterium tuberculosis complex (MTBC), including Mycobacterium tuberculosis var. tuberculosis (MTB) and Mycobacterium tuberculosis var. africanum (MAF).

View Article and Find Full Text PDF

On the basis of population genomic and phylogeographic analyses of 1669 lineage 4 (L4) genomes, we find that dispersal of L4 has been completely dominated by historical migrations out of Europe. We demonstrate an intimate temporal relationship between European colonial expansion into Africa and the Americas and the spread of L4 tuberculosis (TB). Markedly, in the age of antibiotics, mutations conferring antimicrobial resistance overwhelmingly emerged locally (at the level of nations), with minimal cross-border transmission of resistance.

View Article and Find Full Text PDF

Although clofazimine is used to treat multidrug-resistant tuberculosis (MDR-TB), there is scant information on its effectiveness and safety. The aim of this retrospective, observational study was to evaluate these factors as well as the tolerability of clofazimine in populations in Brazil, where it was administered at a daily dose of 100 mg·day (body weight ≥45 kg) as part of a standardised MDR-TB treatment regimen until 2006 (thereafter pyrazinamide was used).All MDR-TB patients included in the Sistema de Informação de Tratamentos Especiais da Tuberculose (SITETB) individual electronic register were analysed.

View Article and Find Full Text PDF